April 15, 2019

Adare Acquires Egalet’s Proprietary “ParvuletTM” Technology Platform

PRINCETON, N.J. & WAYNE, Pa.–(BUSINESS WIRE)–Adare Pharmaceuticals, Inc. today announced that it has entered into an agreement with Egalet Corporation (OTCQX: ZCOR), to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property. The technology is protected by several patents granted in the United States, Canada and Europe with patent life ranging from five to 10 years. Using commonly used pharmaceutical excipients, the technology enables single-dose


Leave Comment


Your Name *
Your Email *
Your Website

Comment *